FDA Sniffs Asthma Drugs Over Child Safety Concerns

Law360, New York (November 26, 2007, 12:00 AM EST) -- Safety officials at the Food and Drug Administration will meet this week to discuss the rare, but potentially fatal, side effects of GlaxoSmithKline Plc's top-selling asthma drugs Serevent and Advair in children.

The advisory panel, which will meet from Tuesday to Thursday of this week, comes after a scathing October report in which FDA staff concluded that the two asthma medications, as well as Novartis' Foradil, may have “an unfavorable risk-benefit ratio” for children's asthma.

The drugs contain the active ingredient salmeterol which may cause adverse...
To view the full article, register now.